Sun Pharmaceutical Industries Ltd. has announced new clinical findings for its investigational once-weekly GLP-1 receptor agonist, Utreglutide (GL0034), at ObesityWeek® 2025, held between November 4–7 in Atlanta, USA. The company presented two separate poster studies highlighting weight-loss, metabolic improvements, and liver-fat reduction in people with obesity.
The first study focused on participants with obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Among 48 enrolled participants, those receiving GL0034 experienced meaningful improvements after approximately 14 weeks of treatment.
Participants in the treatment arm achieved an average 6.8% reduction in body weight and a similar percentage drop in waist circumference, equal to roughly 3.7 inches. The study also reported a notable decrease in liver-fat content, with nearly one-third of treated participants recording more than a 30% reduction—an important marker for MASLD progression.
Additionally, uric-acid levels declined by about 11.5% compared with only 0.6% in the placebo group. The most common side effects were gastrointestinal in nature, including nausea and diarrhoea, but were generally mild to moderate.
A second short-term proof-of-concept study evaluated GL0034 in individuals with overweight or obesity but without diabetes. Over 10 weeks, the treatment group recorded a placebo-corrected weight loss of 6.5%, which remained consistent through Week 14.
Researchers also observed improvements in cardiometabolic markers. Total cholesterol fell by nearly 12%, and LDL cholesterol by around 10%. For participants with higher baseline LDL levels, the reduction was even more pronounced, with average drops of 31 mg/dL. Markers such as ApoB, hs-CRP, and ALT also showed favourable declines, indicating a broader metabolic impact.
Like the first study, gastrointestinal symptoms were the most commonly reported adverse events, affecting fewer than 20% of participants.
Sun Pharma stated that these early results support the continued development of Utreglutide as a potential treatment option for obesity and related metabolic disorders. The company indicated that additional clinical trials are planned to further evaluate long-term safety and effectiveness.
As with all investigational therapies, Sun Pharma cautioned that these findings include forward-looking statements and that actual outcomes may differ as larger studies progress.
